Cargando…

RASopathies and hemostatic abnormalities: key role of platelet dysfunction

BACKGROUND: Bleeding anomalies have been reported in patients affected by Noonan syndrome. No study has been performed in patients with molecularly confirmed RASopathy. We aimed to characterize the frequency and types of bleeding disorders in patients with RASopathies and evaluate any significant as...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Candia, Francesca, Marchetti, Valeria, Cirillo, Ferdinando, Di Minno, Alessandro, Rosano, Carmen, Pagano, Stefano, Siano, Maria Anna, Falco, Mariateresa, Assunto, Antonia, Boccia, Giovanni, Magliacane, Gerardo, Pinna, Valentina, De Luca, Alessandro, Tartaglia, Marco, Di Minno, Giovanni, Strisciuglio, Pietro, Melis, Daniela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8638204/
https://www.ncbi.nlm.nih.gov/pubmed/34857025
http://dx.doi.org/10.1186/s13023-021-02122-7
_version_ 1784608904926199808
author Di Candia, Francesca
Marchetti, Valeria
Cirillo, Ferdinando
Di Minno, Alessandro
Rosano, Carmen
Pagano, Stefano
Siano, Maria Anna
Falco, Mariateresa
Assunto, Antonia
Boccia, Giovanni
Magliacane, Gerardo
Pinna, Valentina
De Luca, Alessandro
Tartaglia, Marco
Di Minno, Giovanni
Strisciuglio, Pietro
Melis, Daniela
author_facet Di Candia, Francesca
Marchetti, Valeria
Cirillo, Ferdinando
Di Minno, Alessandro
Rosano, Carmen
Pagano, Stefano
Siano, Maria Anna
Falco, Mariateresa
Assunto, Antonia
Boccia, Giovanni
Magliacane, Gerardo
Pinna, Valentina
De Luca, Alessandro
Tartaglia, Marco
Di Minno, Giovanni
Strisciuglio, Pietro
Melis, Daniela
author_sort Di Candia, Francesca
collection PubMed
description BACKGROUND: Bleeding anomalies have been reported in patients affected by Noonan syndrome. No study has been performed in patients with molecularly confirmed RASopathy. We aimed to characterize the frequency and types of bleeding disorders in patients with RASopathies and evaluate any significant association with laboratory findings. PATIENTS AND METHODS: Forty-nine individuals (PTPN11, n = 27; SOS1, n = 7; RIT1, n = 3; SPRED1, n = 1; LZTR1, N = 3; RAF1, n = 2; BRAF, n = 4; MEK1, n = 1; MEK2, n = 1), and 49 age- and sex-matched controls were enrolled. The “Paediatric Bleeding Questionnaire Scoring Key” was administered to patients and families. Laboratory screening tests including clotting factors dosing, platelet count, Prothrombin Time and Partial Thromboplastin Time, were employed both in patients and controls to characterize the bleeding diathesis. A subgroup of 29/49 patients and 29/49 controls was also tested for platelet function. RESULTS: Regardless of the gene involved, pathological paediatric bleeding scores were recorded in 14/49 (28.5%) patients. Indeed, 7 were mutated in PTPN11, 3 in SOS1, 2 in RIT1, 1 in BRAF, and 1 in MEK1. Compared to patients with normal bleeding scores, those with pathologic bleeding score showed higher prevalence of splenomegaly (p = 0.006), prolonged aPTT (p = 0.04), lower levels of coagulation factor V (FV, p = 0.001), FVII (p = 0.003), FX (p = 0.0008) and FXIII (p = 0.002), higher vWAg (p = 0.04), and lower platelet sensitivity to Ristocetin (p = 0.001), arachidonic acid (AA) (p = 0.009) and collagen (p = 0.01). The presence of hematomas inversely correlated with factor V (p = 0.002), factor VII (p = 0.003), factor X (p = 0.002) and factor XIII (p = 0.004) levels, and directly correlated with platelet response to collagen (p = 0.02) and AA (p = 0.01). The presence of splenomegaly directly correlated with the presence of hematoma (p = 0.006), platelet response to Ristocetin (p = 0.04) and AA (p = 0.04), and inversely correlated with factor V levels (p = 0.03). CONCLUSIONS: Patients with RASopathies and a bleeding tendency exhibit multiple laboratory abnormalities, including platelet-related disorders. Splenomegaly is frequently detected and might be a suggestive sign for qualitative platelet dysfunction. A comprehensive clinical assessment should be carried out at diagnosis, during the follow-up and before any surgical procedures. Since there is currently no consensus on management of bleeding complications, it is important that physicians closely monitor these patients.
format Online
Article
Text
id pubmed-8638204
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-86382042021-12-02 RASopathies and hemostatic abnormalities: key role of platelet dysfunction Di Candia, Francesca Marchetti, Valeria Cirillo, Ferdinando Di Minno, Alessandro Rosano, Carmen Pagano, Stefano Siano, Maria Anna Falco, Mariateresa Assunto, Antonia Boccia, Giovanni Magliacane, Gerardo Pinna, Valentina De Luca, Alessandro Tartaglia, Marco Di Minno, Giovanni Strisciuglio, Pietro Melis, Daniela Orphanet J Rare Dis Research BACKGROUND: Bleeding anomalies have been reported in patients affected by Noonan syndrome. No study has been performed in patients with molecularly confirmed RASopathy. We aimed to characterize the frequency and types of bleeding disorders in patients with RASopathies and evaluate any significant association with laboratory findings. PATIENTS AND METHODS: Forty-nine individuals (PTPN11, n = 27; SOS1, n = 7; RIT1, n = 3; SPRED1, n = 1; LZTR1, N = 3; RAF1, n = 2; BRAF, n = 4; MEK1, n = 1; MEK2, n = 1), and 49 age- and sex-matched controls were enrolled. The “Paediatric Bleeding Questionnaire Scoring Key” was administered to patients and families. Laboratory screening tests including clotting factors dosing, platelet count, Prothrombin Time and Partial Thromboplastin Time, were employed both in patients and controls to characterize the bleeding diathesis. A subgroup of 29/49 patients and 29/49 controls was also tested for platelet function. RESULTS: Regardless of the gene involved, pathological paediatric bleeding scores were recorded in 14/49 (28.5%) patients. Indeed, 7 were mutated in PTPN11, 3 in SOS1, 2 in RIT1, 1 in BRAF, and 1 in MEK1. Compared to patients with normal bleeding scores, those with pathologic bleeding score showed higher prevalence of splenomegaly (p = 0.006), prolonged aPTT (p = 0.04), lower levels of coagulation factor V (FV, p = 0.001), FVII (p = 0.003), FX (p = 0.0008) and FXIII (p = 0.002), higher vWAg (p = 0.04), and lower platelet sensitivity to Ristocetin (p = 0.001), arachidonic acid (AA) (p = 0.009) and collagen (p = 0.01). The presence of hematomas inversely correlated with factor V (p = 0.002), factor VII (p = 0.003), factor X (p = 0.002) and factor XIII (p = 0.004) levels, and directly correlated with platelet response to collagen (p = 0.02) and AA (p = 0.01). The presence of splenomegaly directly correlated with the presence of hematoma (p = 0.006), platelet response to Ristocetin (p = 0.04) and AA (p = 0.04), and inversely correlated with factor V levels (p = 0.03). CONCLUSIONS: Patients with RASopathies and a bleeding tendency exhibit multiple laboratory abnormalities, including platelet-related disorders. Splenomegaly is frequently detected and might be a suggestive sign for qualitative platelet dysfunction. A comprehensive clinical assessment should be carried out at diagnosis, during the follow-up and before any surgical procedures. Since there is currently no consensus on management of bleeding complications, it is important that physicians closely monitor these patients. BioMed Central 2021-12-02 /pmc/articles/PMC8638204/ /pubmed/34857025 http://dx.doi.org/10.1186/s13023-021-02122-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Di Candia, Francesca
Marchetti, Valeria
Cirillo, Ferdinando
Di Minno, Alessandro
Rosano, Carmen
Pagano, Stefano
Siano, Maria Anna
Falco, Mariateresa
Assunto, Antonia
Boccia, Giovanni
Magliacane, Gerardo
Pinna, Valentina
De Luca, Alessandro
Tartaglia, Marco
Di Minno, Giovanni
Strisciuglio, Pietro
Melis, Daniela
RASopathies and hemostatic abnormalities: key role of platelet dysfunction
title RASopathies and hemostatic abnormalities: key role of platelet dysfunction
title_full RASopathies and hemostatic abnormalities: key role of platelet dysfunction
title_fullStr RASopathies and hemostatic abnormalities: key role of platelet dysfunction
title_full_unstemmed RASopathies and hemostatic abnormalities: key role of platelet dysfunction
title_short RASopathies and hemostatic abnormalities: key role of platelet dysfunction
title_sort rasopathies and hemostatic abnormalities: key role of platelet dysfunction
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8638204/
https://www.ncbi.nlm.nih.gov/pubmed/34857025
http://dx.doi.org/10.1186/s13023-021-02122-7
work_keys_str_mv AT dicandiafrancesca rasopathiesandhemostaticabnormalitieskeyroleofplateletdysfunction
AT marchettivaleria rasopathiesandhemostaticabnormalitieskeyroleofplateletdysfunction
AT cirilloferdinando rasopathiesandhemostaticabnormalitieskeyroleofplateletdysfunction
AT diminnoalessandro rasopathiesandhemostaticabnormalitieskeyroleofplateletdysfunction
AT rosanocarmen rasopathiesandhemostaticabnormalitieskeyroleofplateletdysfunction
AT paganostefano rasopathiesandhemostaticabnormalitieskeyroleofplateletdysfunction
AT sianomariaanna rasopathiesandhemostaticabnormalitieskeyroleofplateletdysfunction
AT falcomariateresa rasopathiesandhemostaticabnormalitieskeyroleofplateletdysfunction
AT assuntoantonia rasopathiesandhemostaticabnormalitieskeyroleofplateletdysfunction
AT bocciagiovanni rasopathiesandhemostaticabnormalitieskeyroleofplateletdysfunction
AT magliacanegerardo rasopathiesandhemostaticabnormalitieskeyroleofplateletdysfunction
AT pinnavalentina rasopathiesandhemostaticabnormalitieskeyroleofplateletdysfunction
AT delucaalessandro rasopathiesandhemostaticabnormalitieskeyroleofplateletdysfunction
AT tartagliamarco rasopathiesandhemostaticabnormalitieskeyroleofplateletdysfunction
AT diminnogiovanni rasopathiesandhemostaticabnormalitieskeyroleofplateletdysfunction
AT strisciugliopietro rasopathiesandhemostaticabnormalitieskeyroleofplateletdysfunction
AT melisdaniela rasopathiesandhemostaticabnormalitieskeyroleofplateletdysfunction